What happens when people try to forget something? What are the consequences of instructing people to intentionally forget a sentence? Recent studies employing the item-method directed forgetting paradigm have shown that to-be-forgotten (TBF) items are, in a subsequent task, emotionally devaluated relative to to-be-remembered (TBR) items, an aftereffect of memory selection (Vivas, Marful, Panagiotidou & Bajo, 2016). As such, distractor devaluation by attentional selection generalizes to memory selection. In this study, we use the item-method directed forgetting paradigm to test the effects of memory selection and inhibition on truth judgments of ambiguous sentences. We expected the relative standing of an item in the task (i.e., whether it was instructed to be remembered or forgotten) to affect the truthfulness value of that item, making TBF items less valid/truthful than TBR items. As predicted, ambiguous sentences associated with a "Forget" cue were subsequently judged as less true than sentences associated with a "Remember" cue, suggesting that instructions to intentionally forget a statement can produce changes in the validity/truthfulness of that statement. To our knowledge, this is the first study to show an influence of memory processes involved in selection and forgetting on the perceived truthfulness of sentences.

Download full-text PDF

Source
http://dx.doi.org/10.1111/sjop.12365DOI Listing

Publication Analysis

Top Keywords

memory selection
12
memory processes
8
processes involved
8
involved selection
8
selection forgetting
8
intentionally forget
8
item-method directed
8
directed forgetting
8
forgetting paradigm
8
tbf items
8

Similar Publications

Background: Immunotherapy of Alzheimer's disease (AD) is a promising approach to reducing the accumulation of beta-amyloid, a critical event in the onset of the disease. Targeting the group II metabotropic glutamate receptors, mGluR2 and mGluR3, could be important in controlling Aβ production, although their respective contribution remains unclear due to the lack of selective tools.

Method: 5xFAD mice were chronically treated by a brain penetrant camelid single domain antibody (VHH or nanobody) that is an activator of mGluR2.

View Article and Find Full Text PDF

Background: Dysregulated GABA/somatostatin (SST) signaling has been implicated in psychiatric and neurodegenerative disorders. The inhibition of excitatory neurons by SST+ interneurons, particularly through α5-containing GABAA receptors (α5-GABAAR), plays a crucial role in mitigating cognitive functions. Previous research demonstrated that an α5-positive allosteric modulator (α5-PAM) mitigates working memory deficits and reverses neuronal atrophy in aged mice.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Department of Bioengineering, University of California, Los Angeles, CA, USA, Los Angeles, CA, USA.

Background: The initiation of amyloid plaque deposition signifies a crucial stage in Alzheimer's disease (AD) progression, which often coincides with the disruption of neural circuits and cognitive decline. While the role of excitatory-inhibitory balance is increasingly recognized in AD pathophysiology, targeted therapies to modulate this balance remain underexplored. This study investigates the effect of perampanel, a selective non-competitive AMPA receptor antagonist, in modulating neurophysiological changes in hAPP-J20 transgenic Alzheimer's mice.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, Patiala, India.

Background: Neuroinflammation plays an important role in progression of Alzheimer's disease (AD). Interlukin-6 (IL-6) is well identified marker in initiating and regulating inflammation, and formation of senile plaques in brain. Therefore, simultaneous inhibition of both IL-6 and acetylcholinesterase (AChE) may be an effective strategy for AD.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Actinogen Medical, Sydney, Australia.

Background: Selecting the optimal dose for clinical development is especially problematic for drugs directed at CNS-specific targets. For drugs with a novel mechanism of action, these problems are often greater. We describe Xanamem's clinical pharmacology, including the approach to dose selection and proof-of-concept studies.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!